Fig. 6: Peripheral virus shedding decreases in dual meganuclease-treated mice.
From: Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo
a Experimental timeline of intravaginal HSV-1 infection, meganuclease treatment and viral reactivations with JQ1. b HSV loads in DRGs from control infected mice reactivated with 3 weekly JQ1 injections and infected mice treated with dual therapy unreactivated, or reactivated with 3 weekly JQ1 injections with n = 8 per group; p = 0.0055, and 0.0198 (ordinary one-way Anova, multiple comparisons) for CTRL + JQ1 vs AAV/MN no JQ1 and for CTRL + JQ1 vs AAV/MN + JQ1, respectively. c, d HSV titers in vaginal swabs collected daily from day 1 to 4 post JQ1 injections (red arrows) from control (c) and dual meganuclease-treated (d) infected mice. Area under the curve (AUC) analysis after the first (e), second (f), and third (g) JQ1 reactivation from control infected mice (n = 8) and infected mice treated with dual therapy, both reactivated with 3 weekly JQ1 injections (n = 8). p values (unpaired one-tailed Mann–Whitney test) are indicated. Each graph shows individual and mean values with standard deviation. The AAV viral loads are shown in Supplemental Fig. 9i. Source data are provided as a Source Data file.
